top of page
Optimising Immunoglobulin Dosing in Secondary Immunodeficiency due to Haematological Malignancies
OPTIMAL is investigating how immune profiling can identify patients who are most likely to benefit from immunoglobulin therapy and inform the best dosing and treatment duration. Studies in people with blood cancers combine measures of immune function with pharmacokinetic and pharmacodynamic analyses, with the aim of supporting more personalised treatment.
Our Team
Prof Jason Roberts, University of Queensland (Lead)
Mr Jamie Jackson, University of Queensland (PhD Candidate, Lead)
Dr Andrea Henden, Royal Brisbane and Women’s Hospital
Dr Midori Nakagaki, Royal Brisbane and Women’s Hospital
Prof Erica Wood, Monash University
bottom of page